A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Ensartinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 19 Dec 2017 Planned number of patients changed from 144 to 152.
- 19 Dec 2017 Planned End Date changed from 30 Jun 2020 to 1 Dec 2018.
- 19 Dec 2017 Planned primary completion date changed from 31 Jan 2019 to 1 Sep 2018.